A simulation to evaluate screening for helicobacter pylori infection in the prevention of peptic ulcers and gastric cancers

Health Care Management Science

Volumn 5, Issue 4, 2002, Pages 249-258

  Davies, Ruth ^a   Crabbe, David ^a   Roderick, Paul ^a   Goddard, Jonathan R ^a   Raftery, James ^b   Patel, Praful ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Helicobacter pylori; Planning; Screening; Simulation

Indexed keywords

ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; ECONOMICS; EVALUATION; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; ISOLATION AND PURIFICATION; MALE; MASS SCREENING; MIDDLE AGED; PEPTIC ULCER; RISK FACTOR; STATISTICS; STOMACH TUMOR; UNITED KINGDOM; UTILIZATION REVIEW;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ENGLAND; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PEPTIC ULCER; RISK FACTORS; STOMACH NEOPLASMS; WALES;

EID: 0036831231     PISSN: 13869620     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020326005465     Document Type: Conference Paper

References (28)

1. M. Bachmann, Personal communication (1999).
2. British National Formulary, Spring 2000.
3. H.T.O. Davies and R. Davies, Simulating health systems: Modelling problems and software solutions, European Journal of Operational Research 87 (1995) 35-44.
4. R. Davies, S.C. Brailsford, P.J. Roderick, C. Canning and D. Crabbe, Using simulation modelling for evaluating screening services for diabetic retinopathy, Journal of the Operational Research Society 51 (2000) 476-484.
5. Eurogast Study Group, Epidemiology of, and risk factors for, Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations, Gut 34 (1993) 1672-1676.
6. R.A. Feldman, J.J. Deeks and S.J.W. Evans, The Helicobacter pylori Serology Study Group, Multi-laboratory comparison of eight commercially available Helicobacter pylori serology kits, European Journal of Clinical Microbiology of Infectious Diseases 14 (1995) 428-433.
7. D. Foreman, Helicobacter pylori infection and cancer, in: Helicobacter Pylori Infection, eds. M.J.G. Farthing and S.E. Patchett (The Royal Society of Medicine Press Ltd., 1998) pp. 71-78.
8. D. Forman, P. Webb and J. Parsonnet, Helicobacter pylori and gastric cancer, Lancet 343 (1994) 243-244.
9. M.J. Gardner and C. Osmond, Interpretation of disease time trends: Is cancer on the increase? A simple cohort technique and its relationship to more advanced models, Journal of Epidemiology and Community Health 37 (1983) 274-8.
10. R.F. Harvey personal communication from the Yate, Bristol screening study (2000).
11. Hospital Episode Statistics (HES) for England for 1997, Department of Health, London, personal communication (1998).
12. E.J. Kuipers, A.S. Pena, G. van-Kamp, A.M. Uyterlinde, G. Pals, N.F. Pels, E. Kurz-Pohlmann and S.G. Meuwissen, Seroconversion for Helicobacter pylori, Lancet 342 (1993) 328-231.
13. J.H. Kurata and A.H. Nogawa, Meta-analysis of risk factors for peptic ulcer - nonsteroidal antiinflammatory drugs, Helicobacter pylori, Journal of Clinical Gastroenterology 24 (1997) 2-17.
14. T. Lind, S. Veldhuyzen van Zanten, P. Unge et al., Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH 1 Study, Helicobacter 1 (1996) 138-143.
15. Morbidity statistics from general practice - 4th National Study 91-92, OPCS Series MB5, No. 3 (London, HMSO, 1995).
16. L.J. Murray, E.E. McCrum, A.E. Evans and K.B. Bamford, Epidemiology of Helicobacter pylori infection among 4742 randomly selected subjects from Northern Ireland, International Journal Epidemiology 26 (1997) 880-887.
17. NHS Trust reference costs (2000). http://www.doh.gov.uk/nhsexec/refcosts. htm.
18. A. Netten and J. Dennett, Unit costs of community care, Canterbury, Personal Social Services Research Unit (University of Kent, 1999).
19. Office for National Statistics, Cancer survival in England and Wales, 1981 and 1989 registrations, Monitor Population and Health (London, HMSO, 1998).
20. Office for National Statistics, Gastric cancer mortality in England (1950-1994), Personal communication (1998).
21. Office for National Statistics, Gastric cancer mortality in England (1950-1994), Personal communication (1999).
22. Office for National Statistics, Mortality data for England and Wales, Personal communication (1999).
23. C. Osmond, Using age period and cohort models to estimate future mortality rate, International Journal of Epidemiology 14 (1985) 124-129.
24. J. Parsonnet, R.A. Harris, H.M. Hack and D.K. Owens, Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: A mandate for clinical trials, Lancet 348 (1996) 150-154.
25. P. Patel, S. Khulusi, M.A. Mendall, R. Lloyd, R. Jazrawi, J.D. Maxwell and T.C. Northfield, Prospective screening of dyspeptic patients before endoscopy using Helicobacter pylori serology: Subsequent progress of those not endoscoped, Lancet 346 (1995) 1315-1318.
26. SAS Institute Inc., Cary, NC, USA (1996).
27. M. Stone, General population screening for infection with Helicobacter pylori: A realistic option? Journal of Medical Screening 5 (1998) 162-166.
28. M. Woodward, C.E. Morrison and K.E.L. McColl, The prevalence of dyspepsia and use of antisecretory medication in North Glasgow: Role of Helicobacter pylori vs. lifestyle factors, Alimentary Pharmacology and Therapeutics 13 (1999) 1505-1509.